The FDA has approved Lipfendra, the first oral PCSK9 inhibitor, for the treatment of high cholesterol. Two medical experts explain why this matters.
Scientists at @HopkinsMedicine say they found a class of inhibitors that may lead to better, more effective treatments for ...
Morning Overview on MSN
A common blood-pressure pill mixed with a routine antibiotic can trigger kidney injury
Patients who take a calcium-channel blocker for high blood pressure and then receive a prescription for clarithromycin, one ...
Two professors from Washington State University have designed a dietary supplement meant to ease the addictive nature of nicotine and restrict the negative effects air pollutants have on the body.
Some healthy-looking foods and common pantry staples may interfere with blood pressure medications, potentially reducing ...
CureGene Pharmaceutical today announced that the first participant has been successfully dosed in the U.S. pivotal clinical trial of Evategrel (CG-0255), its proprietary new-generation best-in-class ...
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar ...
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a potential treatment for ...
A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from ...
Researchers from the Universities of Bath and Leeds (UK) have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery. The findings, ...
Kisqali (ribociclib) is broken down by the CYP3A4 enzyme, so drugs or foods that affect this enzyme can change Kisqali levels in your blood. This can make the drug less effective or increase your risk ...
A multicenter phase II study of first-line modified FOLFIRINOX in patients with advanced urachal cancer (ULTIMA; KCSG GU20-03). The impact of neoadjuvant chemotherapy relative dose intensity on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results